ArticleThe American journal of pathology1993
Enhanced tumorigenicity of an Epstein-Barr virus-transformed lymphoblastoid cell line is associated with a unique 1:18 chromosomal translocation and decreased expression of lymphocyte function associated antigen-1a (CD11A).
Article in The American journal of pathology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
- Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
An Epstein-Barr virus-transformed lymphoblastoid cell line was identified that disseminated to multiple organs and grew rapidly when transplanted to severe combined immunodeficient mice. This pattern of growth more closely resembled that of Burkitt's lymphoma cells than that of all other lymphoblastoid cell lines tested. Analysis of the rapidly growing lymphoblastoid cell line showed two distinctive changes. First, all of the cells derived from the tumor had a 1:18 chromosomal translocation [t(1;18)(p32.1;q23.3)]. Second, the lymphoblastoid cell line down-regulated expression of lymphocyte function associated antigen-1a during passage in severe combined immunodeficient mice, but regained expression upon growth in vitro. These two changes seem sufficient to explain the enhanced tumorigenicity of this cell line and may represent examples of changes that lead to more aggressive lymphomas in posttransplant lymphoproliferative disease.
Indexed as
Identifiers
8393615PMC1887022W2415774099What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.